Hiroyuki Yamaguchi

TL;DR: The RELAY trial as mentioned in this paper evaluated erlotinib, an EGFR tyrosine kinase inhibitor (TKI) standard of care, plus ramucirumab, a human IgG1 VEGFR2 antagonist, or placebo in patients with untreated EGFR-mutated metastatic NSCLC.

TL;DR: It is shown that AXL, which is activated by osimertinib, can promote the emergence of tolerant lung cancer cell thus conferring resistance to osimERTinib and proposed the combination of Osimert inib with AXL inhibitor as a potential therapeutic approach in such resistant cancers.

TL;DR: Individuals with tumors positive for MyD88 mutations also harbored the same mutations at a low frequency in peripheral blood mononuclear cells, suggesting that MYD88 mutation-positive precancerous cells originate outside of the CNS and develop into lymphoma after additional genetic hits that confer adaptation to the CNS environment.

TL;DR: It is shown that the human sarcoma cell line HT1080 harbors both NRAS(Q61K) and RAC1(N92I) mutant proteins, which are potential targets for the development of new therapeutic agents.

TL;DR: The results suggest that the level of 20q13.2 amplification correlates with the metastatic potential and tumor progression of CRC, and suggests that 20q 13.2 amplified with ZNF217 is associated with increased metastatic Potential.